The importance of transparency in industry-sponsored multicenter clinical studies [1]

Anesthesia and Analgesia

Volumn 105, Issue 6, 2007, Pages 1861-

  White, Paul F ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; APREPITANT; NEUROKININ 1 RECEPTOR ANTAGONIST;

CLINICAL RESEARCH; CONFLICT OF INTEREST; DECISION MAKING; DRUG APPROVAL; DRUG INDUSTRY; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; MEDICAL AUDIT; MULTICENTER STUDY; PEER REVIEW; POSTOPERATIVE NAUSEA AND VOMITING; PRIORITY JOURNAL; PUBLICATION; RESEARCH ETHICS; TREATMENT OUTCOME; CLINICAL TRIAL; DRUG EFFICACY;

EID: 36549040995     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ane.0000287630.15745.d1     Document Type: Letter

References (10)

1. Gan TJ, Apfel CC, Kovac A, Philip BK, Singla N, Minkowitz H, Habib AS, Knighton J, Carides AD, Zhang H, Horgan KJ, Evans JK, Lawson FC. Aprepitant-PONV Study Group. A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting. Anesth Analg 2007;104:1082-9
2. Gesztesi Z, Scuderi PE, White PF, Wright W, Wender RH, D'Angelo R, Black LS, Dalby PL, MacLean D. Substance P (Neurokinin-1) antagonist prevents postoperative vomiting after abdominal hysterectomy procedures. Anesthesiology 2000;93:931-7
3. Saidman LJ. Unresolved issues relating to peer review, industry support of research, and conflict of interest. Anesthesiology 1994;80:491-2
4. Peterson CJ. Industry support of research and conflict of interest. Anesthesiology 1994;81:270
5. Eger EI. Motivation, bias, and scientific integrity. Anesthesiology 1994;81:270-1
6. Cullen DJ. Ghostwriting in scientific anesthesia journals. Anesthesiology 1997;87:195-6
7. Davidoff F, DeAngelis CD, Drazen JM, Hoey J, Hojgaard L, Horton R, KotNicholls, Nylenna M, Overbeke AJ, Sox HC, Van Der Weyden MB, Wilkes MS. Sponsorship, authorship, and accountability. Lancet 2001;358:854-6
8. Brennan TA, Rothman DJ, Blank L, Blumenthal D, Chimonas SC, Cohen JJ, Goldman J, Kassirer JP, Kimball H, Naughton J, Smelser N. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA 2006;295:429-33
9. Moffatt B, Elliott C. Ghost marketing: pharmaceutical companies and ghostwritten journal articles. Perspect Biol Med 2006;50:18-31
10. Newcombe JP, Kerridge IH. Assessment by human research ethics committees of potential conflicts of interest arising from pharmaceutical sponsorship of clinical research. Intern Med J 2007;37:12-17